Collapse All

27 March 2019

09:00 - 12:30

ISPOR CEE Consortium Chapter Meetings

  • Description
  • Individual Chapters will meet to discuss relevant updates and issues.

    All attendees of Chapter meetings must be registered for ISPOR Warsaw 2019. For questions about the scheduled Chapter meetings and to RSVP please contact Gosia Juszczak-Punwaney, Senior Manager, ISPOR Global Networks -EMEA. Seating is limited.

    Currently scheduled meetings:
    ISPOR Poland Chapter
    ISPOR Ukraine Chapter

    By invitation only.
    Prior RSVP is required.


27 March 2019

13:30 - 15:30

ISPOR CEE Consortium meeting

  • Description
  • ISPOR Regional Chapter leadership representatives and members from the CEE Consortium will meet to update and review current issues.

    All ISPOR CEE Consortium meeting attendees need to be registered to ISPOR Warsaw 2019 and send RSVP to Gosia Juszczak-Punwaney, Senior Manager, ISPOR Global Networks -EMEA. Seating is limited.

    By invitation only.
    Prior RSVP is required.


27 March 2019

14:00 - 19:00

Registration and Exhibits

27 March 2019

15:30 - 16:30

1st Sponsored Educational Symposium

  • Description
  • Details to come.

    Open to all participants.

27 March 2019

16:30 - 16:45

Coffee Break

27 March 2019

16:45 - 17:45

2nd Sponsored Educational Symposium

  • Description
  • Details to come.

    Open to all participants.

27 March 2019

17:45 - 18:00

Coffee Break

27 March 2019

18:00 - 19:00

3rd Sponsored Educational Symposium

  • Description
  • Details to come.

    Open to all participants.

27 March 2019

19:00 - 20:00

Welcome Reception

  • Description
  • Details to come.

    Open to all participants.

28 March 2019

08:00 - 17:30

Registration and Exhibits

28 March 2019

08:30 - 09:00

Morning snack / refreshments in the foyer

28 March 2019

09:00 - 10:30

Opening - Session 1: Aligning Evidence Requirements for Drug Authorization and Coverage – Central and Eastern European (CEE) Countries Insights

  • Description
  • Welcome address from the ISPOR Leadership. 

    The European Medicines Agency (EMA) has offered consultations that are parallel with the European network for Health Technology Assessment (EUnetHTA) since July 2017.

    The consultations allow developers of medicines to obtain feedback from regulators and health technology assessment (HTA) bodies on its evidence-generating plans to support decision-makers on the topics of marketing authorization and reimbursement of new medicines.

    The attractive or acceptable risk-benefit ratio from the EMA perspective might not easily translate into favorable comparative effectiveness and cost-effectiveness from the payers’ perspective. The regulatory approach (ie: early access, PRO based authorization, lack of hard endpoints, survival gain) implies specific consideration from the HTA perspective. Potentially, countries with a more limited healthcare budget would expect stronger evidence and less uncertainty around clinical outcomes in their coverage decision.

    The focus of the session is to reflect on the benefits of the initial consultations, while exploring the CEE countries perspectives through scientific advice from EMA and HTA bodies.

    Session speakers to be announced.


28 March 2019

10:30 - 11:00

Coffee Break

28 March 2019

11:00 - 12:30

Session 2: Health Data, Health Data, and More Health Data: From Quantity to Quality Through Cooperation

  • Description
  • Rising healthcare costs are under increased worldwide scrutiny. Efforts to improve the outcomes for money spent, and to build a value-based healthcare solution are vital. Health data is an increasingly essential ingredient to enhance health systems performance, and healthcare quality, while contributing to scientific discoveries that improve medical treatments and save lives. Value-based healthcarerequires a comprehensive informatics infrastructure for collecting, sharing and analyzing data and information for each population segment along the full cycle of care.

    Discussing and finding ways to strengthen commitment to make better use of available health data and develop new databases, to foster international cooperation in health research and cross-country databases, and ultimately to improve health systems performance and outcomes are priority topics in the CEE countries.

    The session will review the following areas:

    • Manage availability and use of personal health information to enable significant improvements in health, healthcare quality and performance,
    • Engage a greater number of countries participating in multi-country statistical and research projects, and
    • Develop greater standardization of the health data governance frameworks to improve the abilities of CEE countries to benefit from statistical and research uses of data in which there is a public interest.


    Availability, access to, and quality/type of health data needed will be discussed from the perspective of joint clinical assessment, price negotiation and procurement.

    Session speakers to be announced.


28 March 2019

12:30 - 13:30

Lunch

  • Description
  • Open to all delegates.

28 March 2019

13:30 - 15:00

Session 3: Medical Device Assessment and Procurement – Fair and Efficient Access in Countries with Limited Health Budgets

  • Description
  • The medical devices market is less regulated as seen across countries globally. Heterogeneity and specificity of many non-drug products need to be taken into account in HTA and coverage decisions. Several projects related to standardization of medical devices value assessment are underway.

    The session will provide an update on international efforts in advancing methodology and approaches to medical device assessment, present several European countries experiences, and discuss the issue of medical device assessment and procurement in the context of those healthcare systems working within restricted budgets.

    Session speakers to be announced.

28 March 2019

15:00 - 15:15

Coffee break

28 March 2019

15:15 - 16:45

Session 4: How Far We Can Go Common Way in Clinical Evaluation, Data Generation and Joint Procurement and Pricing Negotiations – SWOT Analysis

  • Description
  • All countries face the same problems of managing an aging population, increasing patients’ expectations, availability of promising novel and costly health technologies, and the need for evidence-based coverage decisions navigating budget limitations. Increased dialogue and cooperation between countries, decision makers and stakeholders in general is necessary.

    The challenge of the diversity of the European healthcare systems contributes to the complexity of finding an effective balance between “going it alone” and “joining forces” to support the coverage decision-making process.

    In that context, session delegates will discuss strengths, weaknesses, opportunities and threats of a joint approach to value assessment, procurement and price negotiations that impact access to health technologies in Europe.

    Session speakers to be announced.


28 March 2019

16:45 - 17:00

Closing Remarks

  • Description
  • Speaker to be announced.